NASDAQ:ENTO Entero Therapeutics 10/21/2024 Earnings Report $2.52 +0.01 (+0.40%) As of 05/1/2026 ProfileEarnings HistoryForecast Entero Therapeutics EPS ResultsActual EPS-$10.11Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEntero Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEntero Therapeutics Announcement DetailsQuarterDate10/21/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsEntero Therapeutics' next earnings date is estimated for Wednesday, May 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Entero Therapeutics Earnings HeadlinesEntero Therapeutics (NASDAQ:ENTO) Shares Down 3.4% - Should You Sell?April 25, 2026 | americanbankingnews.comGridAI Technologies Faces Default on Revolving Loan AgreementApril 24, 2026 | tipranks.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.May 5 at 1:00 AM | Brownstone Research (Ad)Entero Therapeutics Inc.December 4, 2025 | wsj.comNASDAQ: ENTO’s Grid AI Strikes Texas Hyperscale Deal as its $50M Industrial Software Platform Enters the AI RaceNovember 19, 2025 | msn.comEntero's Grid AI Announces Major U.S. Expansion and Incoming Leadership to Accelerate AI Infrastructure StrategyNovember 19, 2025 | finance.yahoo.comSee More Entero Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Entero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entero Therapeutics and other key companies, straight to your email. Email Address About Entero TherapeuticsEntero Therapeutics (NASDAQ:ENTO) (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases. Entero’s pipeline features multiple lead candidates in varying stages of clinical development. By employing proprietary formulation platforms, the company seeks to optimize oral bioavailability and site‐specific release profiles, enabling precise treatment of localized GI pathology. Entero works closely with academic medical centers, clinical research organizations and patient advocacy groups to advance its programs through regulatory milestones, with the goal of delivering novel treatment options for both adult and pediatric patient populations. Founded in 2018 and headquartered in Massachusetts, Entero Therapeutics operates with a network of partners and investigators across the United States. The company maintains a lean organizational structure to support focused development and commercialization activities in the GI space. Through disciplined clinical execution and strategic alliances, Entero aims to become a leading provider of specialized therapies that address significant unmet needs in gastrointestinal health.View Entero Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings AppLovin (5/6/2026)ARM (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
